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Background. The link between endogenous estrogen, coronary artery disease (CAD), and death in postmenopausal women is
uncertain.Weanalyzedtheassociationbetweendeathandbloodlevelsofestroneinpostmenopausalwomenwithknowncoronary
artery disease (CAD) or with a high-risk factor score for CAD. Methods. 251 postmenopausal women age 50–90 years not on
estrogentherapy.Fastingbloodforestroneandheartdiseaseriskfactorswerecollectedatbaseline.Womenweregroupedaccording
to their estrone levels (<15 and ≥15pg/mL). Fatal events were recorded after 5.8 ± 1.4 years of followup. Results. The Kaplan-
Meier survival curve showed a signiﬁcant trend (P = 0.039) of greater all-cause mortality in women with low estrone levels
(<15pg/mL). Cox multivariate regression analysis model adjusted for body mass index, diabetes, dyslipidemia, family history, and
estrone showed estrone (OR = 0.45; P = 0.038) as the only independent variable for all-cause mortality. Multivariate regression
model adjusted for age, body mass index, hypertension, diabetes, dyslipidemia, family history, and estrone showed that only age
(OR = 1.06; P = 0.017) was an independent predictor of all-cause mortality. Conclusions.P o s t m e n o p a u s a lw o m e nw i t hk n o w n
CAD or with a high-risk factor score for CAD and low estrone levels (<15pg/mL) had increased all-cause mortality.
1.Background
Endogenous estrogens are associated with greater vascular
protection in premenopausal women [1]. Estradiol is the
mainandmostactiverepresentativeofendogenousestrogens
in premenopausal women. This protection occurs through
genomic and nongenomic actions [2]. The antiatherogenic
and antithrombogenic eﬀects of estradiol slow the process
of atherosclerosis, and therefore cardiovascular events occur
later in women compared to men [3]. In postmenopausal
women, a signiﬁcant reduction in estradiol production
occurs due to ovarian failure. The natural protection ceases
to exist, and at this stage, a gradual and progressive increase
begins in cardiovascular events in women. However, hor-
mone replacement therapy with estrogen and progesterone
was not eﬀective in primary or secondary prevention of car-
diovascular events in postmenopausal women [4, 5]. Several
hypotheses have been considered to justify these results,
among them, the characteristics of exogenous estrogens,
the high dose used, the association of progestins, and time
since menopause [6]. It is known, however, that in post-
menopausal women production of endogenous estrogen is
very low. In this period, estrone is the main representative
of the endogenous estrogens and is produced by several
tissues, especially adipose tissue. Estrone is the result of the
process of aromatization of androstenedione that occurs
in fat cells [7]. Obese women have higher plasma concen-
trations of estrone [8]. However, the inﬂuence of estrone
on cardiovascular protection in postmenopausal women is
unknown. A previous study showed higher plasma levels of2 The Scientiﬁc World Journal
estrone in obese patients with coronary artery disease (CAD)
or at high risk for coronary heart disease [9]. The same
study also showed that increased plasma levels of estrone
were associated with a nonsigniﬁcant trend toward a lower
incidence of cardiovascular events. However, the follow-up
period was only 2 years. The current study analyzed, in the
same population, the eﬀects of serum estrone in death from
all causes in a long-term followup.
2. Methods
2.1. Study Populations. Participants were 251 postmenopau-
sal women aged 50 to 90 years who had known CAD or were
at high risk for CAD based on a risk factor score of 4 or
more points, using the score developed for use in raloxifene
trials [10]. Patients using postmenopausal hormone therapy
and with advanced stage or clinically limiting disease were
not included in the study. Women were patients in the
ambulatory care clinic of a tertiary cardiology hospital, who
were followed from March 2004 to December 2010. Primary
end-point was death of any cause. Follow-up data were
obtained through telephone calls and validated if given by
a family member. Five patients were missed.
2.2. Clinical Characteristics. Baseline clinical characteristics
included body mass index (BMI), blood pressure, medica-
tion use, and history of cardiac procedures and cardiac
events. Laboratory tests for biologic CAD risk factors includ-
ed fasting venous blood glucose, triglycerides, total choles-
terol, HDL-cholesterol, LDL-cholesterol, C-reactive protein,
and estrone. Risk factors for CAD were diabetes mellitus
(fasting blood glucose ≥126mg/dL [11]); hypertension (dia-
stolic blood pressure ≥90mmHg [12]); dyslipidemia (tri-
glycerides ≥200mg/dL and/or LDL cholesterol ≥ 130mg/dL
[13]); family history (CAD occurring in parents before age
55 for men, 65 for women and siblings); at least 6 months
of daily smoking of any kind or quantity of tobacco [14];
obesity status based on BMI (kg/m2) deﬁned by the National
Institutes of Health and the World Health Organization as
normal (≥18.5 to <25), overweight (≥25 to <30), and obese
(≥30) [15].
2.3. Laboratory Measurements. Morning blood was collected
after a requested 12-hour fast. Estrone samples were mea-
sured on frozen plasma by a manual processing radioim-
munoassay method using DSL 8700 (Diagnostic Systems
Laboratories, Inc., Webster, TX, USA) with reference values
14.1–102.6pg/mL for postmenopausal women. Based on the
lower limit of the reference value in this laboratory, low
e s t r o n el e v e l sw e r ed e ﬁ n e da s<15pg/mL (43 patients) ver-
sus ≥15pg/mL (208 patients). High sensitivity C-reactive
protein was measured using an immunoturbidimetric ultra-
sensitive detection method, (Roche Diagnostics GmbH, D-
68298 Mannheim, Germany), with a normal reference value
<0.5mg/dL.
The ethics committee of the Heart Institute (InCor)
approved the study design, and all participants provided
written informed consent.
2.4. Statistical Analysis. A sample size of at least 200 patients,
with 100 subjects per treatment group, was determined to
give 80% power to detect a 20% diﬀerence in the incidence
of cardiovascular events with a 5% signiﬁcance level.
The chi-square test was used for analysis of categorical
variables, and Student’s t test or 2-way ANOVA analysis
was used for continuous variables. Mortality analyses used
Kaplan-Meier estimation curves stratiﬁed by low or normal
estrone levels (<15 and ≥15pg/mL, resp.). Three models
of Cox multivariate regression analysis were done. Model
1 was adjusted for age, hypertension, body mass index,
diabetes,dyslipidemia,andestrone;model 2wasadjustedfor
hypertension, body mass index, diabetes, dyslipidemia, and
estrone; model 3 was adjusted for body mass index, diabetes,
dyslipidemia, and estrone. The statistical software used was
SAS 9.2 (SAS Institute Inc, Cary, NC, USA).
3. Results
Baselineclinicalandlaboratorycharacteristicsofthepatients
and group comparisons of estrone levels of <15 and
≥15pg/mLareshowninTable 1.Estronehistogramisshown
in Figure 1. Mean estrone levels were, respectively, 10.8 ±2.1
and 27.6 ± 12.9pg/mL (P<0.001). Women with a low
estrone level were older (72±7.5v e r s u s6 9 .2±6.7y e a r s ;P =
0.016), thinner (27.9±4.6v e r s u s3 0±5.4kg/m 2; P = 0.020),
and had less hypertension (95% versus 88%; P = 0.036),
diabetes(37%versus62%;P = 0.003),andlowertriglyceride
(148.9±63.1 versus178.5±123.8mg/dL;P = 0.023),glucose
(107.5 ± 32.8 versus 137.3 ± 59.5mg/dL;P = 0.002), and C-
reactive protein levels (0.45 ±0.55 versus 0.70 ±1.31mg/dL;
P = 0.045). Women with BMI ≥30kg/m2 were younger
(70.5 ± 7.4v e r s u s6 8 .7 ± 6.3; P = 0.046) and had more
hypertension (92% versus 99%; P = 0.009), less diabetes
(52% versus 31%; P = 0.001), and lower HDL (54.3 ± 13.2
versus 50.9 ± 11.3mg/dL;P = 0.033) and LDL (117 ± 35.8
versus 107 ± 35.6mg/dL;P = 0.029). Estrone was greater in
patients with BMI ≥30kg/m2 (22.4 ± 9.9v e r s u s2 8 .2 ± 16.4;
P = 0.001) (Table 2). Death was associated with higher age
(69.2 ± 6.9v e r s u s7 2 .6 ± 7.2y e a r s ;P = 0.010) and almost
signiﬁcant higher prevalence of hypertension (96% versus
88%; P = 0.051) and LDL plasma levels (111.2 ± 37.1v e r s u s
121.3 ± 25.2mg/dL; P = 0.054) (Table 3). There were 32
deaths, 27 (84%) attributed to cardiovascular disease (23 to
CAD and 4 to stroke), 3 to pneumonia, and 2 to cancer (1
lung and 1 bone). The Kaplan-Meier survival curve showed a
signiﬁcant trend (P = 0.039) of greater all-cause mortality
in women with low estrone levels (<15pg/mL) (Figure 2).
Three models of Cox regression analysis were done: model
1 was adjusted for age, body mass index, hypertension,
diabetes, dyslipidemia, family history, and estrone; model 2
was adjusted for body mass index, hypertension, diabetes,
dyslipidemia, family history, and estrone; model 3 was
adjusted for body mass index, diabetes, dyslipidemia, family
history, and estrone. In model 1, age (OR = 1.05 [95%CI:
1.00–1.11]; P = 0.016) was the only independent predictor
of all-cause mortality; in model 2, hypertension (OR = 2.44
[95%CI: 0.83–7.20]; P = 0.030); in model 3, estrone (OR =
0.45 [95%CI: 0.21–0.95]; P = 0.038) (Table 4).The Scientiﬁc World Journal 3
Table 1: Baseline clinical characteristics and comparison of estrone <15pg/mL and estrone ≥15pg/mL in 251 patients.
Baseline N = 251 Estrone <15pg/mL, N = 43 (17%) Estrone ≥15pg/mL, N = 208 (83%) P
Age (years) 69.7 ± 7.07 2 ±7.56 9 .2 ±6.7 0.016
Body mass index (kg/m2)2 9 .7 ± 5.32 7 .9 ±4.63 0 ±5.4 0.020
Hypertension 238 (95) 38 (88) 200 (96) 0.036
Diabetes 144 (57) 16 (37) 128 (62) 0.003
Dyslipidemia 233 (93) 40 (93) 193 (93) 0.956
Family history 170 (68) 31 (72) 139 (67) 0.641
Coronary artery disease 189 (75) 35 (81) 154 (74) 0.308
Smoking 25 (10) 4 (10) 21 (10) 0.837
SBP (mm Hg) 141.8 ± 18.4 137.7 ±21.2 142.6 ±17.7 0.110
DBP (mm Hg) 83 ±9.98 0 .7 ± 10.88 3 .5 ±9.6 0.092
Triglycerides (mg/dL) 173.4 ±116.1 148.9 ±63.1 178.5 ±123.8 0.023
Total cholesterol (mg/dL) 199.3 ± 41.1 200.7 ±40.7 199 ±41.2 0.808
HDL cholesterol (mg/dL) 52.8 ±12.55 4 .8 ± 13.15 2 .4 ±12.3 0.247
LDL cholesterol (mg/dL) 112.7 ±36 116.1 ±37.8 112 ±35.7 0.496
Glucose (mg/dL) 132.2 ± 56.9 107.5 ±32.8 137.3 ±59.5 0.002
C reactive protein (mg/dL) 0.65 ±1.22 0.45 ± 0.55 0.70 ±1.31 0.045
Estrone (pg/mL) 24.9 ±13.41 0 .8 ±2.12 7 .6 ±12.9 <0.001
SBP: systolic blood pressure; DBP: diastolic blood pressure.
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Figure 1: Histogram of estrone plasma levels.
4. Discussion
This study of long-term followup showed that serum estrone
level <15pg/mL was an independent risk factor for increased
mortality from all causes in postmenopausal women with
CHD or at high risk for CAD. Almost all deaths (84%) were
from cardiovascular origin and from myocardial infarction.
The current study conﬁrmed the possible beneﬁcial eﬀects of
estrone suggested by our previous study of short-term fol-
lowup in the same population [9]. However, the association
of estrone and CAD is unknown. Few studies have analyzed
this association, and they have not shown any correlation
between estrone plasma levels and CAD [16–18]. In a recent
nested case-control study, estrone levels did not correlate
with the incidence of CAD [19].
Estrone is the main endogenous estrogen in post-
menopausal women. Nevertheless, estrone eﬀects on the vas-
cular system are signiﬁcantly lower than estradiol mainly
presentinthepremenopausalperiod[20].Appropriatephys-
iological levels of estrone in postmenopausal women may
therefore bring additional beneﬁts in cardiovascular protec-
tion. In postmenopausal women, a reduction occurs in the
number and activity of estrogen receptors in tissues, and
therefore more potent endogenous or exogenous estrogens
are not necessary in this period. Likewise, the doses of exoge-
nous estrogens are not physiological and are generally above
the baseline needs. Estrogen therapy signiﬁcantly increases
the serum levels of estrone far above the levels observed in
postmenopausal women. Estrone is also the main precursor
of the small amount of estradiol still present in post-
menopausal women. Estrone can then be the most suitable
endogenous estrogen during the postmenopausal period for
maintenance of basic physiological needs at this time. The
estrone in postmenopausal women is produced mainly in
adipose tissue, and obese women have higher serum estrone.
However, obesity is associated with metabolic syndrome
characterized by alterations in glucose metabolism, lipids,4 The Scientiﬁc World Journal
Table 2: Baseline clinical characteristics and comparison of body mass index (BMI) <30kg/m2 and ≥30kg/m2 in 246 patients.
IMC <30 kg/m2 (N = 141) IMC ≥30kg/m2 (N = 105) P
Age (years) 70.5 ±7.46 8 .7 ±6.3 0.046
Hypertension 129 (92) 104 (99) 0.009
Diabetes 73 (52) 33 (31) 0.001
Dyslipidemia 131 (93) 97 (92) 0.667
Family history 94 (67) 76 (72) 0.337
Coronary artery disease 36 (26) 24 (23) 0.629
Smoking 14 (10) 11 (10) 0.888
SBP (mm Hg) 139.6 ±19.8 144.6 ±15.9 0.026
DBP (mm Hg) 81.8 ±10.48 4 .67 ±8.9 0.020
Triglycerides (mg/dL) 160.2 ±81.0 190.9 ±149.3 0.055
Total cholesterol (mg/dL) 202.9 ±41.7 194.7 ±39.9 0.116
HDL cholesterol (mg/dL) 54.3 ±13.25 0 .9 ±11.3 0.033
LDL cholesterol (mg/dL) 117.0 ±35.8 107.0 ±35.6 0.029
Glucose (mg/dL) 128.6 ±57.2 136.9 ±56.3 0.249
C reactive protein (mg/dL) 0.25 ±0.13 0.63 ±0.57 0.779
Estrone (pg/mL) 22.4 ±9.92 8 .2 ±16.4 0.001
SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 3: Baseline clinical characteristics and comparison of 246 patients by survival status (32 deaths).
Alive (N = 214) Death (N = 32) P
Age (years) 69.2 ±6.97 2 .6 ±7.2 0.010
Body mass index 29.7 ±5.22 8 .3 ±5.7 0.157
Hypertension 205 (96) 28 (88) 0.051
Diabetes 93 (43) 13 (41) 0.763
Dyslipidemia 200 (93) 28 (88) 0.227
Coronary artery disease 54 (25) 6 (19) 0.426
Family history 151 (71) 19 (59) 0.202
Smoking 23 (11) 2 (6) 0.432
SBP (mmHg) 141.4 ±18.2 143.1 ±19.7 0.612
DBP (mmHg) 82.9 ±9.88 2 .8 ±10.2 0.938
Triglycerides (mg/dL) 172.2 ±119 170.6 ±101 0.908
Total cholesterol (mg/dL) 198.4 ±41.9 204 ±33.9 0.468
HDL cholesterol (mg/dL) 53.3 ±12.85 0 .6 ±10.7 0.251
LDL cholesterol (mg/dL) 111.2 ±37.1 121.3 ±25.2 0.054
Glucose (mg/dL) 132.6 ±56.4 131.3 ±64.5 0.904
C reactive protein (mg/dL) 0.62 ±1.04 0.85 ±2.12 0.548
Estrone (pg/mL) 25.1 ±13.62 1 .6 ±11.5 0.166
SBP: systolic blood pressure; DBP: diastolic blood pressure.
and presence of hypertension [21]. Inﬂammatory markers,
such as CRP and leptin, are also increased in obese individ-
uals. CRP is also increased in postmenopausal women who
use hormone replacement therapy. In our study, we observed
increased serum levels of CRP in the group of women
with estrone ≥15pg/mL. However, this increase may be due
to the higher prevalence of hypertension, diabetes, serum
triglycerides, and glucose in this group, suggesting a pattern
of metabolic syndrome that is known to increase CRP. Being
estrone protective of the cardiovascular system, the increased
production of estrone in obese women may be a feedback
mechanism for protecting the cardiovascular system in this
population. In our study, estrone ≥15pg/mL may be a factor
to explain the lower mortality despite the high risk proﬁle
for cardiovascular patients. Higher estrone levels remained
an independent variable even after adjustment for body
mass index and prevalence of diabetes and dyslipidemia.
The action of estrone in the metabolism of glucose and
lipid is still controversial [22–25], but direct and indirect
beneﬁcial eﬀects similar to those observed for estradiol, butThe Scientiﬁc World Journal 5
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Figure 2: Kaplan-Meier curve for all causes of deaths according to
estrone levels (<15pg/mL versus ≥15pg/mL).
Table 4: Cox regression multivariate analysis for diﬀerent models
of variable adjustments.
Model Variable Hazard
ratio
95% Conﬁdence
interval P
1 Age 1.05 1.00–1.11 0.016
2 Hypertension 2.44 0.83–7.20 0.030
3 Estrone 0.45 0.21–0.95 0.038
Model 1: adjusted for age, body mass index, hypertension, diabetes,
dyslipidemia, family history, and estrone; 2: adjusted for body mass index,
hypertension,diabetes,dyslipidemia,familyhistory,andestrone;3:adjusted
for body mass index, diabetes, dyslipidemia, family history, and estrone.
of lesser intensity, may also occur with estrone in these
2 pathways. The prevalence of risk factors for CAD was
signiﬁcantly higher in our population. Diabetes was more
prevalent in women with estrone levels ≥15pg/mL (62%
versus37%,P = 0.003),butevenwithaworsecardiovascular
risk proﬁle [26], this was the group that had fewer deaths. In
conclusion, serum estrone levels ≥15pg/mL were associated
with lower mortality from all causes in postmenopausal
women with CHD or at high risk for CAD. Therefore,
we hypothesized that the better prognosis was due to the
p o s s i b l ep r o t e c t i v ee ﬀects of increased physiological levels of
estrone. Nevertheless, this hypothesis should be validated by
al a r g ep r o s p e c t i v es t u d y .
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